Konstantin Poukalov
Founder chez LIANBIO
Fortune : 5 517 $ au 31/03/2024
Profil
Konstantin Poukalov has founded multiple companies.
He founded ARYA Sciences Acquisition Corp.
III in 2020, LianBio in 2019, ARYA Sciences Acquisition Corp.
IV in 2021, and ARYA Sciences Acquisition Corp.
V in 2021.
At ARYA Sciences Acquisition Corp.
III, he held the title of Chief Business Officer from 2020 to 2021.
At LianBio, he is currently serving as the Executive Chairman since 2019.
At ARYA Sciences Acquisition Corp.
IV and ARYA Sciences Acquisition Corp.
V, he is currently serving as the Chief Business Officer since 2021.
Mr. Poukalov also holds current positions at Lyra Therapeutics, Inc. as an Independent Director since 2020, at Perceptive Advisors (Private Equity) as a Managing Director-Strategy since 2019, at Shanghai Lianbio Development Co., Ltd.
as an Executive Director, and at Prolaio, Inc. as a Director.
In his former positions, Mr. Poukalov served as an Independent Director at Landos Biopharma, Inc. from 2019 to 2021.
He was the Chief Financial & Accounting Officer, Executive VP at Kadmon Holdings, Inc. from 2014 to 2018.
He was a Member at Jefferies LLC from 2009 to 2012 and at UBS Investment Bank (US) from 2006 to 2009.
He also held the position of Chief Financial Officer & Executive Vice President at Kadmon Corp.
LLC and Chief Business Officer at ARYA Sciences Acquisition Corp.
II.
Mr. Poukalov completed his undergraduate degree at Stony Brook University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
LIANBIO
0,02% | 15/02/2024 | 17 082 ( 0,02% ) | 5 517 $ | 31/03/2024 |
LYRA THERAPEUTICS, INC.
-.--% | 01/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Konstantin Poukalov
| Sociétés | Poste | Début |
|---|---|---|
| LYRA THERAPEUTICS, INC. | Director/Board Member | 29/01/2020 |
| ARYA SCIENCES ACQUISITION CORP IV | Founder | 01/01/2021 |
| LIANBIO | Founder | 17/07/2019 |
| ARYA SCIENCES ACQUISITION CORP V | Founder | 22/02/2021 |
Shanghai Lianbio Development Co., Ltd.
 Shanghai Lianbio Development Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of LianBio, Shanghai Lianbio Development Co., Ltd. is a private company that manufactures paradigm-shifting medicines to patients. The company is based in Shanghai, China. The CEO of the Chinese company is Debra Yu. | Director/Board Member | - |
Perceptive Advisors (Private Equity)
 Perceptive Advisors (Private Equity) Investment ManagersFinance Perceptive Advisors (Private Equity) (Perceptive Advisors) is a private equity subsidiary of Perceptive Advisors LLC founded in 1999 by Joseph Eric Edelman. The firm is headquartered in New York. | Corporate Officer/Principal | 01/03/2019 |
Prolaio, Inc.
 Prolaio, Inc. BiotechnologyHealth Technology Prolaio, Inc. is a company founded in 2021 that engages in research and development of medical. The company is based in Scottsdale, AZ. | Director/Board Member | - |
Anciens postes connus de Konstantin Poukalov
| Sociétés | Poste | Fin |
|---|---|---|
| LANDOS BIOPHARMA, INC. | Director/Board Member | 27/08/2021 |
| ARYA SCIENCES ACQUISITION III A | Founder | 01/06/2021 |
| ░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Konstantin Poukalov
| Stony Brook University | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| LYRA THERAPEUTICS, INC. | Health Technology |
| LANDOS BIOPHARMA, INC. | Health Technology |
| ARYA SCIENCES ACQUISITION CORP IV | Finance |
| Entreprise privées | 11 |
|---|---|
Kadmon Holdings, Inc.
 Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
Jefferies LLC
 Jefferies LLC Investment Banks/BrokersFinance Jefferies LLC is a global investment bank and institutional securities firm headquartered in New York City. The firm was founded in 1962 and is a subsidiary of Jefferies Group LLC, ultimately held by Jefferies Financial Group, Inc. (NYSE: JEF). Jefferies provides corporate clients with research and execution services in equity, fixed income, and foreign exchange markets, as well as a full range of investment banking services such as underwriting, mergers and acquisitions, restructuring and recapitalization, and other advisory services, with all businesses operating in the Americas, Europe and Asia. | Finance |
UBS Investment Bank (US)
 UBS Investment Bank (US) Investment Banks/BrokersFinance UBS Investment Bank provides investment banking and securities brokerage services. Its clients include institutional and corporate clients, intermediaries, governments, and hedge funds. The firm also provides merger and acquisition advisory, private placement, investment research, foreign exchange, equity, and leverage finance advisory services. The firm is headquartered in San Francisco, CA. | Finance |
Kadmon Corp. LLC
 Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | Health Technology |
Perceptive Advisors (Private Equity)
Perceptive Advisors (Private Equity) Investment ManagersFinance Perceptive Advisors (Private Equity) (Perceptive Advisors) is a private equity subsidiary of Perceptive Advisors LLC founded in 1999 by Joseph Eric Edelman. The firm is headquartered in New York. | Finance |
ARYA Sciences Acquisition Corp. II
 ARYA Sciences Acquisition Corp. II Financial ConglomeratesFinance ARYA Sciences Acquisition Corp. II is blank check company which formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, which refer to as its initial business combination. The company was founded by Joseph Edelman, Adam Stone & Michael Altman on February 20, 2020 and is headquartered in New York, NY. | Finance |
ARYA Sciences Acquisition Corp. III
 ARYA Sciences Acquisition Corp. III Financial ConglomeratesFinance ARYA Sciences Acquisition Corp III is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, which it refers to as its initial business combination. It has not yet selected any business combination target. The company was founded by Joseph Edelman, Adam Stone, Michael Altman, and Konstantin Poukalov on March 27, 2020 and is headquartered in New York, NY. | Finance |
| LianBio | |
ARYA Sciences Acquisition Corp. V
 ARYA Sciences Acquisition Corp. V Financial ConglomeratesFinance Arya Sciences Acquisition Corp. V is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Adam Stones, Joseph Eric Edelman, Michael R. Altman, and Konstantin Poukalov on February 22, 2021 and is headquartered in New York, NY. | Finance |
Shanghai Lianbio Development Co., Ltd.
Shanghai Lianbio Development Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of LianBio, Shanghai Lianbio Development Co., Ltd. is a private company that manufactures paradigm-shifting medicines to patients. The company is based in Shanghai, China. The CEO of the Chinese company is Debra Yu. | Health Technology |
Prolaio, Inc.
Prolaio, Inc. BiotechnologyHealth Technology Prolaio, Inc. is a company founded in 2021 that engages in research and development of medical. The company is based in Scottsdale, AZ. | Health Technology |
